Form 4: Apogee Therapeutics Director Jennifer Fox Acquires Stock Options

Jennifer Fox, a director at Apogee Therapeutics, acquired options to purchase 10,370 shares of common stock on June 5, 2024.

Summary

• On June 5, 2024, Jennifer Fox, a director of Apogee Therapeutics, Inc., was granted options to purchase 10,370 shares of the company's common stock.
• The exercise price of these options is $43.85 per share.
• The options will vest on the one-year anniversary of the grant date, contingent upon Ms. Fox's continued service to Apogee Therapeutics.
• The options expire on June 5, 2034.
• A Power of Attorney was executed on June 2, 2024, authorizing Jane Pritchett Henderson, Matthew Batters, Ryan A. Murr, Melanie Neary and Candice Johnson to act on behalf of Jennifer Fox in matters related to Section 16(a) filings.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. The granting of options is generally viewed as a positive incentive for company leadership.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates